Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: To study whether the effect of allopurinol on improvement of endothelial dysfunction in chronic heart failure (CHF) translates into improved exercise capacity and to examine whether allopurinol also improves B-type natriuretic peptide (BNP), the other important prognostic marker of CHF. Design: Randomised, double blind, placebo controlled crossover trial. Setting: Teaching hospital. Patients: 50 patients with CHF (New York Heart Association functional classes II and III) were recruited. Interventions: 50 patients with CHF were randomly assigned to three months’ treatment with allopurinol (300 mg/day) or placebo. At two and three months into treatment, they underwent a modified Bruce exercise protocol and a six minute walk test. Blood was taken for BNP and haemoglobin analysis. Results: Neither exercise test was altered by allopurinol. However, plasma BNP concentrations fell significantly (p = 0.035) with allopurinol (11.9 pmol/l) versus placebo (14.4 pmol/l). Haemoglobin concentrations also fell highly significantly with allopurinol (p = 0.001). Conclusions: An important negative finding is that despite high hopes for it, allopurinol had no effect on exercise capacity in CHF. On the other hand, allopurinol did reduce BNP, which is the best available surrogate marker for prognosis in CHF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Heitzer, T., Schlinzig, T., Krohn, K., Meinertz, T., & Münzel, T. (2001) · Circulation · doi:10.1161/hc4601.099485 · Cited by 1,961
The clinical implications of endothelial dysfunction
Widlansky, M. E., Gokce, N., Keaney, J. F., & Vita, J. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00994-x · Cited by 1,749
Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients
Perticone, F., Ceravolo, R., Pujia, A., Ventura, G., Iacopino, S., Scozzafava, A., Ferraro, A., Chello, M., Mastroroberto, P., Verdecchia, P., et al. (2001) · Circulation · doi:10.1161/01.cir.104.2.191 · Cited by 1,059
Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Self-citationAllopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics With Mild Hypertension
Butler, R., Morris, A. D., Belch, J. J. F., Hill, A., & Struthers, A. D. (2000) · Hypertension · doi:10.1161/01.hyp.35.3.746 · Cited by 463
Self-citationAllopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy
Cappola, T. P., Kass, D. A., Nelson, G. S., Berger, R. D., Rosas, G. O., Kobeissi, Z. A., Marbán, E., & Hare, J. M. (2001) · Circulation · doi:10.1161/hc4501.098928 · Cited by 436
Danesh, J. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1699 · Cited by 339
Xanthine Oxidase Inhibition Reverses Endothelial Dysfunction in Heavy Smokers
Guthikonda, S., Sinkey, C., Barenz, T., & Haynes, W. G. (2003) · Circulation · doi:10.1161/01.cir.0000046448.26751.58 · Cited by 225
Cited by
Pacher, P., Nivorozhkin, A., & Szabó, C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.6 · Cited by 1,218
“Model Disease or Trigger Mode of XO Inhibition Effects of XO Inhibition Reference Mouse Coronary ligation-induced HF Allopurinol Allopurinol doubled the survival and improved contractility and response to isoproterenol both in vivo and in isolated muscle; allopurinol also reduced the elevated XO activity in mice with…”
BackgroundInfluentialTreating Oxidative Stress in Heart Failure: Past, Present and Future
van der Pol, A., van Gilst, W. H., Voors, A. A., & van der Meer, P. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1320 · Cited by 813
Uric acid and cardiovascular disease
Ndrepepa, G. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.05.046 · Cited by 498
The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor
D’Oria, R., Schipani, R., Leonardini, A., Natalicchio, A., Perrini, S., Cignarelli, A., Laviola, L., & Giorgino, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5732956 · Cited by 376
Noman, A., Ang, D. S., Ogston, S., Lang, C. C., & Struthers, A. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60391-1 · Cited by 348
Self-citation
Metadata
- Authors
- Gavin, A. D., & Struthers, A. D.
- Venue
- Heart
- Publisher
- BMJ
- Published
- 2005-05-13
- Volume
- 91
- Issue
- 6
- Pages
- 749-753
- ISSN
- 1355-6037 (ISSN-L)
- 1468-201X
- OpenAlex
- W2088738068
- Cited by
- 106
- References
- 9
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.